Audio Podcast Transcript
Welcome to the CDER Small Business and Industry Assistance (SBIA) Podcast Series. Today’s topic: PDUFA – A Time for Change.
October 1st, 2017 marked the date for a host of changes at FDA’s Center for Drug Evaluation and Research or CDER as the new Fiscal Year (2018) took effect. One set of changes comes from the re-authorization of the Prescription Drug User Fee Act or PDUFA.
PDUFA was created by Congress in 1992 with the cooperation of both FDA and the drug industry. Prior to the first enactment of PDUFA, FDA's premarket review of drug product applications was understaffed, unpredictable, and slow. In response, Congress passed PDUFA, which authorized the FDA to collect fees to make the drug review process more efficient, without compromising drug safety, efficacy, and quality. Program enhancements have been made with each 5-year reauthorization that incorporate advances in regulatory science into drug development. Enhancements included in PDUFA VI, which support the 21st Century Cures Act, include the following
Enhanced Review Transparency and Communication: You may remember “the Program” model from PDUFA V to promote transparency and communication between the FDA review team and the applicant, increase the efficiency and effectiveness of the first cycle review process, and minimize the number of review cycles necessary for approval. FDA is now applying this model to the review of all New Molecular Entity New Drug Applications and original Biologics License Applications, including applications that are resubmitted following a Refuse-to-File decision.
Promoting Innovation through Enhanced Communication: FDA will maintain dedicated drug development communication and training staffs, focused on enhancing communication between FDA and sponsors during drug development.
Ensuring Sustained Success of the Breakthrough Therapy Program: Breakthrough therapy designation is intended to expedite the development and review of drug and biological products for serious or life-threatening diseases or conditions when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies. PDUFA VI provides funding and resources to this program to enable FDA to continue to work closely with sponsors throughout the designation, development, and review process.
Early Consultation on the Use of New Surrogate Endpoints: Early consultation between the FDA and sponsors can now occur when the sponsor intends to use a biomarker as a new surrogate endpoint that has never been previously used as the primary basis for product approval in the proposed context of use.
Advancing the Development of Drugs for Rare Diseases: CDER’s Rare Disease Program staff will provide their expertise on approaches to studying and reviewing such drugs, continue to foster collaborations in the development of tools and data to support rare disease drug development, and facilitate interactions to increase awareness of FDA programs and engagement of patients in the decision-making process.
Advancing Development of Drug-Device and Biologic-Device Combination Products: PDUFA VI streamlines the process for combination product review and improves the Agency’s ability to assess workload and allocate resources to the review of combination products.
Advancing the Use of Complex Innovative Trial Designs and Model Informed Drug Development: FDA will conduct activities to facilitate the development and application of exposure-based, biological, and statistical models derived from preclinical and clinical data sources.
Enhancement and Modernization of the FDA Drug Safety System: FDA will continue to use user fees to enhance and modernize post-marketing drug safety evaluation through the expansion of the Sentinel System and timely and effective evaluation and communication of post-marketing safety findings related to human drugs.
PDUFA VI also has a new enhanced fee structure designed to achieve increased predictability, stability, and efficiency, which is described in FDA’s Guidance for Industry: Assessing User Fees Under the Prescription Drug User Fee Amendments of 2017. A one-time application fee is still due upon submission, but FDA has eliminated supplement fees. An application fee requiring clinical data is approximately 2.4 million dollars, and without clinical data approximately 1.2 million dollars. The annual post-approval fees, which used to include the product fees and establishment fees, now solely consist of a program fee of approximately 304 thousand dollars. In addition, if a company now submits an application in the middle of a fiscal year, it will not be charged a program fee until the next fiscal year.
Under PDUFA VI, a greater proportion of the target revenue allocation has shifted to more predictable fee-paying types (20% to application fees; 80% to Program fees) to provide FDA with a more stable revenue source. PDUFA VI also eliminates a provision under which applicants could apply for a waiver or refund of user fees or “the fees-exceed-costs waiver.” FDA has already begun to implement many of these activities and goals. It will be exciting to see how new drug review, the U.S. drug safety system and ultimately the American public, benefit in the next five years under PDUFA VI.
A link to this full SBIA Chronicle article and more information about CDER’s SBIA Program may be found at: https://www.fda.gov/cdersbia.
Thanks for tuning in!